Galena Biopharma Inc. as announced that the preclinical data from its NeuVax program was revealed during a presentation given Tuesday at the Progress in Vaccination Against Cancer (PIVAC) Conference that is being held in Winchester, England.
NeuVax is comprised of an immunodominant peptide taken from the HER2 protein’s extracellular region, which is found in ovarian, pancreatic and breast cancer.
The NeuVax poster, which is called “Preclinical study on the efficacy of NeuVax peptide vaccine against human Her2+/ HLA-A2.1+ ovarian and pancreatic cancer,” showed the results of HLA-A2 transgenic mice that NeuVax, combined with recombinant mouse GM-CSF, was used to immunize. NeuVax resulted in a delayed-type hypersensitivity (DTH) reaction.
“The findings from this preclinical mouse model provide scientific bases about the efficacy of NeuVax vaccination in hampering ovarian and pancreatic tumor progression by showing both DTH reactions and NeuVax specific CD8+ T cells,” Galena EVP and CMO Dr. Bijan Nejadnik said. “Importantly, the expression of PD-1 on activated CD8+ T cells suggests an opportunity to investigate the efficacy of NeuVax in combination with PD-1 inhibitors. We appreciate the work and dedication on this study run by our partners at the University of Torino in Italy.”